| Date | Title | Description | |
|---|---|---|---|
| 07 Nov 2024 | On P&L | The Company releases the press release related to the first nine months 2024 financial results | Download |
| 07 Nov 2024 | On P&L | The Company releases the first nine months 2024 financial results presentation | Download |
| 24 Oct 2024 | On corporate transactions | ROVI completes the strategic review of its CDMO business | Download |
| 31 Jul 2024 | On P&L | The Company releases the press release related to the first half 2024 financial results | Download |
| 31 Jul 2024 | On P&L | The Company releases the first half 2024 financial results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Feb 2020 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 26 Feb 2020 | Annual Corporate Governance Report | ROVI releases the 2019 Annual Corporate Governance Report | Download |
| 26 Feb 2020 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2019 annual report regarding remuneration of the members of the Board of Directors | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
| 21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
| 24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |